ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
36 announcements with these filters
Solara Active Pharma Sciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure details equity ownership across various investor categories.
Solara delivered its best profitability in five years despite ongoing Ibuprofen pricing and raw material challenges.
Solara's Q2 FY27 delivered record EBITDA and PAT in five years, driven by 33% revenue growth. Base business strength offset Ibuprofen headwinds, which is now nearing breakeven.
Solara Active Pharma Sciences Limited allotted 8,300 equity shares under its 2018 ESOP plan. The exercise of these options realized Rs. 0.31 Crore for the company.
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹417.3 Cr (+33.1% YoY) and net profit of ₹28.5 Cr for Q2 FY27.
Solara Active Pharma received an ESG rating of 63 ('Strong' category) from Crisil ESG Ratings for the fiscal year 2026, an upgrade from the prior year.
Solara Active Pharma Sciences will issue a Final Reminder-cum-Forfeiture Notice to holders of partly paid-up rights equity shares regarding outstanding call money payments.
Solara Active Pharma Sciences Ltd has scheduled a board meeting on October 16, 2026, to consider and approve the financial results for the period ended September 30, 2026.
Solara Active Pharma Sciences is notifying physical shareholders to update their PAN, KYC, and nomination details per SEBI circulars. This is a routine regulatory compliance intimation.
Solara Active Pharma Sciences Limited held its Ninth Annual General Meeting on September 18, 2026. Shareholders transacted business, including approving related party transactions.
Solara Active Pharma Sciences Limited received a rectification order dropping an earlier income tax demand of Rs. 161.92 Crore. The demand was reduced to nil.
Solara Active Pharma Sciences Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. This is a periodic regulatory compliance disclosure.
Solara Active Pharma Sciences Limited has issued the notice for its Ninth Annual General Meeting, scheduled to be held on September 18, 2026.
Solara Active Pharma Sciences approved the conversion of 2,79,582 partly paid-up rights shares into fully paid-up equity. The conversion followed receipt of pending first and final call monies.
Solara Active Pharma Sciences Limited allotted 2,250 equity shares under its ESOP scheme. This allotment slightly increases the company's paid-up share capital to Rs. 48.06 Crore.
Solara Active Pharma Sciences Limited allotted 2,250 equity shares following ESOP exercises. The allotment increases the company's paid-up share capital slightly to Rs. 48.06 Crore.
Solara Active Pharma Sciences revised the appointment date for Mr. Ajit Manocha as Chief Information Officer and Senior Management Personnel to August 17, 2026.
Solara achieved record EBITDA/PAT despite significant geopolitical headwinds in West Asia impacting raw material costs.
Solara Active Pharma Sciences allotted 2,250 equity shares under its ESOP scheme. This allotment marginally increases the company's paid-up share capital.
Solara Active Pharma Sciences allotted 2,250 equity shares under its 2018 ESOP scheme. This exercise realized Rs. 8.44 Lakh in capital for the company.
Solara Active Pharma Sciences appointed Mr. Ajit Manocha as Chief Information Officer. He is designated as Senior Management Personnel effective August 10, 2026.
Solara reported Q1'27 overall revenues of ₹384.3 Crore and PAT of ₹16.3 Crore. Base business revenues grew 24% YoY to ₹307.7 Crore.
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹381.6 Cr (+19.6% YoY) and net profit of ₹16.3 Cr (+55.2% YoY) for Q1 FY27.
The company filed its quarterly shareholding pattern under Regulation 31. This routine regulatory disclosure details shareholding distribution across various investor categories.
Solara Active Pharma Sciences scheduled a board meeting on July 23, 2026. The board will consider unaudited standalone and consolidated financial results for Q1 FY27.
Solara Pharma issued a final reminder for unpaid call money on rights shares. Failure to pay by July 27, 2026, will lead to forfeiture of those shares.
Solara Active Pharma Sciences allotted 70,000 equity shares under its ESOP Plan 2024, raising Rs. 2.63 Crore. This increases the paid-up capital and reflects employee stock option exercises.
Solara Active Pharma Sciences allotted 2,250 equity shares under its ESOP 2018, realizing Rs. 0.08 Crore. This is a routine employee benefit exercise with minimal dilution impact.
Solara Active Pharma clarified that recent trading volume spurts are not due to undisclosed material events. The company remains compliant with all SEBI disclosure regulations.
Solara Active Pharma submitted its Annual Secretarial Compliance Report for FY 2025-26. The auditor confirmed zero material non-compliances, ensuring robust governance standards.